Powered by

-Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration

Nov 20, 2018 - ENP Newswire

MENLO PARK - Adverum Biotechnologies, Inc.(Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022 for patients with wet age-related macular degeneration (wet AMD).

'We are excited to announce the first patient dosed in our OPTIC phase 1 trial assessing a potential single intravitreal administration of ADVM-022 for wet AMD,' said Leo...